Baruch Wolach1,2, Ronit Gavrieli3,4, Martin de Boer5, Karin van Leeuwen5, Ofir Wolach6, Galia Grisaru-Soen7, Arnon Broides8,9, Amos Etzioni10, Raz Somech3,11, Dirk Roos5. 1. Pediatric Hematology Clinic and the Laboratory for Leukocyte Function, Meir Medical Center, 59 Tchernichovsky St., 44281 Kfar Saba, Israel. wolachb@post.tau.ac.il. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. wolachb@post.tau.ac.il. 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. The Laboratory for Leukocyte Function, Meir Medical Center, Kfar Saba, Israel. 5. Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 6. Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel. 7. Pediatric Infectious Diseases Unit, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 8. Immunology Clinic, Soroka University Medical Center, Beer Sheva, Israel. 9. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. 10. Meyer Children's Hospital and Rappaport Faculty of Medicine, The Technion, Haifa, Israel. 11. Immunology Service, Department of Pediatrics, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
Abstract
PURPOSE: Chronic granulomatous disease (CGD) is an innate immune deficiency disorder of phagocytes, resulting from mutations in the components of the NADPH oxidase complex that impair the synthesis of oxygen radicals, thus rendering patients susceptible to recurrent infections and excessive hyperinflammatory responses. The most common autosomal recessive form of CGD is p47phox deficiency, which is often clinically milder than the more common X-linked recessive form. Here, we report data on genetics, clinical and biochemical findings in 17 CGD patients of Kavkazi origin with the nonsense mutation c.579G>A in the NCF1 gene, leading to p47phox deficiency. METHODS: Diagnosis was based on detailed clinical evaluation, respiratory burst activity by cytochrome c reduction and dihydrorhodamine-1,2,3 (DHR) assay by flow cytometry, expression of p47phox by immunoblotting and molecular confirmation by DNA sequence analysis. RESULTS: Twelve male and five female patients with median age at onset of 2.5 years (range 1 day to 9 years) were included in the study. The present cohort displays an encouraging 88% overall long-term survival, with median follow-up of 17 years. Clinical manifestations varied from mild to severe expression of the disease. Correlation between genotype and phenotype is unpredictable, although the Kavkazi patients were more severely affected than other patients with p47phox deficiency. CONCLUSIONS: Kavkazi CGD patients harbor a common genetic mutation that is associated with a heterogeneous clinical phenotype. Early diagnosis and proper clinical management in an experienced phagocytic leukocyte center is imperative to ensure favorable patient outcome. New treatment strategies are ongoing, but results are not yet conclusive.
PURPOSE:Chronic granulomatous disease (CGD) is an innate immune deficiency disorder of phagocytes, resulting from mutations in the components of the NADPH oxidase complex that impair the synthesis of oxygen radicals, thus rendering patients susceptible to recurrent infections and excessive hyperinflammatory responses. The most common autosomal recessive form of CGD is p47phoxdeficiency, which is often clinically milder than the more common X-linked recessive form. Here, we report data on genetics, clinical and biochemical findings in 17 CGDpatients of Kavkazi origin with the nonsense mutation c.579G>A in the NCF1 gene, leading to p47phoxdeficiency. METHODS: Diagnosis was based on detailed clinical evaluation, respiratory burst activity by cytochrome c reduction and dihydrorhodamine-1,2,3 (DHR) assay by flow cytometry, expression of p47phox by immunoblotting and molecular confirmation by DNA sequence analysis. RESULTS: Twelve male and five female patients with median age at onset of 2.5 years (range 1 day to 9 years) were included in the study. The present cohort displays an encouraging 88% overall long-term survival, with median follow-up of 17 years. Clinical manifestations varied from mild to severe expression of the disease. Correlation between genotype and phenotype is unpredictable, although the Kavkazi patients were more severely affected than other patients with p47phoxdeficiency. CONCLUSIONS: Kavkazi CGDpatients harbor a common genetic mutation that is associated with a heterogeneous clinical phenotype. Early diagnosis and proper clinical management in an experienced phagocytic leukocyte center is imperative to ensure favorable patient outcome. New treatment strategies are ongoing, but results are not yet conclusive.
Authors: Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland Journal: Clin Infect Dis Date: 2014-12-23 Impact factor: 9.079
Authors: Johan Bylund; Kelly L MacDonald; Kelly L Brown; Piotr Mydel; L Vincent Collins; Robert E W Hancock; David P Speert Journal: Eur J Immunol Date: 2007-04 Impact factor: 5.532
Authors: Juan D Matute; Andres A Arias; Nicola A M Wright; Iwona Wrobel; Christopher C M Waterhouse; Xing Jun Li; Christophe C Marchal; Natalie D Stull; David B Lewis; MacGregor Steele; James D Kellner; Weiming Yu; Samy O Meroueh; William M Nauseef; Mary C Dinauer Journal: Blood Date: 2009-08-19 Impact factor: 22.113
Authors: Baldassarre Martire; Roberto Rondelli; Annarosa Soresina; Claudio Pignata; Teresa Broccoletti; Andrea Finocchi; Paolo Rossi; Marco Gattorno; Marco Rabusin; Chiara Azzari; Rosa M Dellepiane; Maria C Pietrogrande; Antonino Trizzino; Paolo Di Bartolomeo; Silvana Martino; Luigi Carpino; Fausto Cossu; Franco Locatelli; Rita Maccario; Paolo Pierani; Maria C Putti; Achille Stabile; Luigi D Notarangelo; Alberto G Ugazio; Alessandro Plebani; Domenico De Mattia Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: Mustafa Yavuz Köker; Yıldız Camcıoğlu; Karin van Leeuwen; Sara Şebnem Kılıç; Işıl Barlan; Mustafa Yılmaz; Ayşe Metin; Martin de Boer; Hüseyin Avcılar; Türkan Patıroğlu; Alişan Yıldıran; Olcay Yeğin; Ilhan Tezcan; Özden Sanal; Dirk Roos Journal: J Allergy Clin Immunol Date: 2013-07-31 Impact factor: 10.793
Authors: Philipp Kruger; Mona Saffarzadeh; Alexander N R Weber; Nikolaus Rieber; Markus Radsak; Horst von Bernuth; Charaf Benarafa; Dirk Roos; Julia Skokowa; Dominik Hartl Journal: PLoS Pathog Date: 2015-03-12 Impact factor: 6.823
Authors: Faris Ghalib Bakri; Michelle Mollin; Sylvain Beaumel; Bénédicte Vigne; Nathalie Roux-Buisson; Adel Mohammed Al-Wahadneh; Raed Mohammed Alzyoud; Wail Ahmad Hayajneh; Ammar Khaled Daoud; Mohammed Elian Abu Shukair; Mansour Fuad Karadshe; Mahmoud Mohammad Sarhan; Jamal Ahmad Wadi Al-Ramahi; Julien Fauré; John Rendu; Marie Jose Stasia Journal: Front Immunol Date: 2021-03-05 Impact factor: 7.561